

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version
4.0

Revision Date:
17.06.2025

SDS Number:
1731675-00017

Date of last issue: 14.04.2025
Date of first issue: 05.06.2017

Section 1: Identification

Product identifier : Moxifloxacin Solid Formulation

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

Manufacturer or supplier's details

Company : MSD
Address : 50 Tuas West Drive
Singapore - Singapore 638408
Telephone : +1-908-740-4000
Emergency telephone number : 65 6697 2111 (24/7/365)
E-mail address : EHSDATASTEWARD@msd.com

Section 2: Hazard identification

Classification of the substance or mixture

Acute toxicity (Oral) : Category 4
Serious eye damage/eye irritation : Category 2
Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure : Category 2 (Liver)

GHS Label elements, including precautionary statements

Hazard pictograms	:		
Signal word	:	Warning	
Hazard statements	:	H302 Harmful if swallowed. H319 Causes serious eye irritation. H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Liver) through prolonged or repeated exposure.	

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version 4.0	Revision Date: 17.06.2025	SDS Number: 1731675-00017	Date of last issue: 14.04.2025 Date of first issue: 05.06.2017
----------------	------------------------------	------------------------------	-------------------------------------------------------------------

Precautionary statements

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	>= 70 -< 90
Cellulose	9004-34-6	>= 30 -< 50

Section 4: First-aid measures

Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.

Moxifloxacin Solid Formulation

Version 4.0 Revision Date: 17.06.2025 SDS Number: 1731675-00017 Date of last issue: 14.04.2025
Date of first issue: 05.06.2017

Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed

Risks : Harmful if swallowed.
Causes serious eye irritation.
Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures**Extinguishing media**

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version
4.0

Revision Date:
17.06.2025

SDS Number:
1731675-00017

Date of last issue: 14.04.2025
Date of first issue: 05.06.2017

Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not swallow.
Do not get in eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version 4.0	Revision Date: 17.06.2025	SDS Number: 1731675-00017	Date of last issue: 14.04.2025 Date of first issue: 05.06.2017
----------------	------------------------------	------------------------------	-------------------------------------------------------------------

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 µg/m ³ (OEB 1)	Internal
Cellulose	9004-34-6	PEL (long term)	10 mg/m ³	SG OEL
		TWA	10 mg/m ³	ACGIH

Appropriate engineering control measures : Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Material

Section 9: Physical and chemical properties

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version 4.0 Revision Date: 17.06.2025 SDS Number: 1731675-00017 Date of last issue: 14.04.2025
Date of first issue: 05.06.2017

Appearance	:	solid
Colour	:	pink
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version 4.0 Revision Date: 17.06.2025 SDS Number: 1731675-00017 Date of last issue: 14.04.2025
Date of first issue: 05.06.2017

Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: Not applicable
Particle characteristics	
Particle size	: No data available

Section 10: Stability and reactivity

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of exposure	: Skin contact Ingestion Eye contact
------------------------------------------	--------------------------------------------

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity	: Acute toxicity estimate: 1,886 mg/kg Method: Calculation method
---------------------	----------------------------------------------------------------------

Components:

Moxifloxacin HCL:

Acute oral toxicity	: LD50 (Rat): 1,320 mg/kg LD50 (Mouse): > 435 mg/kg LD50 (Monkey): 1,500 mg/kg
---------------------	--------------------------------------------------------------------------------------

Cellulose:

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version 4.0 Revision Date: 17.06.2025 SDS Number: 1731675-00017 Date of last issue: 14.04.2025
Date of first issue: 05.06.2017

Skin corrosion/irritation

Not classified based on available information.

Components:

Moxifloxacin HCL:

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Moxifloxacin HCL:

Species	:	Rabbit
Result	:	Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

Moxifloxacin HCL:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: positive
		Test Type: Chromosome aberration test in vitro Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
		Test Type: in vitro micronucleus test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Application Route: Oral Result: negative

Cellulose:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	------------------------------------------------------------------------

Moxifloxacin Solid FormulationVersion
4.0Revision Date:
17.06.2025SDS Number:
1731675-00017Date of last issue: 14.04.2025
Date of first issue: 05.06.2017

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo

: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Moxifloxacin HCL:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: LOAEL: 500 mg/kg body weight
Result: Effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Monkey
Application Route: Oral
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: negative

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 20 mg/kg body weight
Symptoms: Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat

Moxifloxacin Solid FormulationVersion
4.0Revision Date:
17.06.2025SDS Number:
1731675-00017Date of last issue: 14.04.2025
Date of first issue: 05.06.2017Application Route: Ingestion
Result: negative

Effects on foetal development

: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative**STOT - single exposure**

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Liver) through prolonged or repeated exposure.

Components:**Moxifloxacin HCL:**

Target Organs	:	Liver
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Moxifloxacin HCL:**

Species	:	Rat
LOAEL	:	100 mg/kg
Application Route	:	Oral
Exposure time	:	4 Weeks

Species	:	Rat
NOAEL	:	100 mg/kg
Application Route	:	Oral
Exposure time	:	13 Weeks
Target Organs	:	Liver
Symptoms	:	Liver disorders

Species	:	Rat
NOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	6 Months
Target Organs	:	Liver
Symptoms	:	Liver disorders

Species	:	Monkey
NOAEL	:	50 mg/kg
Application Route	:	Oral
Exposure time	:	4 Weeks
Symptoms	:	No adverse effects

Species	:	Monkey
---------	---	--------

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version 4.0 Revision Date: 17.06.2025 SDS Number: 1731675-00017 Date of last issue: 14.04.2025
Date of first issue: 05.06.2017

NOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Gastrointestinal tract
Symptoms : Vomiting

Species : Monkey
Application Route : Oral
Exposure time : 26 Weeks
Target Organs : Liver
Symptoms : Liver disorders

Cellulose:

Species : Rat
NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Moxifloxacin HCL:

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

Section 12: Ecological information

Toxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Bioaccumulative potential

No data available

Moxifloxacin Solid FormulationVersion
4.0Revision Date:
17.06.2025SDS Number:
1731675-00017Date of last issue: 14.04.2025
Date of first issue: 05.06.2017**Mobility in soil**

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number : Not applicable

UN proper shipping name : Not applicable

Transport hazard class(es) : Not applicable

Subsidiary risk : Not applicable

Packing group : Not applicable

Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable

UN proper shipping name : Not applicable

Transport hazard class(es) : Not applicable

Subsidiary risk : Not applicable

Packing group : Not applicable

Labels : Not applicable

Packing instruction (cargo aircraft) : Not applicable

Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable

UN proper shipping name : Not applicable

Transport hazard class(es) : Not applicable

Subsidiary risk : Not applicable

Packing group : Not applicable

Labels : Not applicable

EmS Code : Not applicable

Marine pollutant : Not applicable

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version 4.0 Revision Date: 17.06.2025 SDS Number: 1731675-00017 Date of last issue: 14.04.2025 Date of first issue: 05.06.2017

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subject to the requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable
Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable
Regulations

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 17.06.2025

Further information

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD compile the Safety Data eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/> Sheet

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average
SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-

SAFETY DATA SHEET



Moxifloxacin Solid Formulation

Version
4.0

Revision Date:
17.06.2025

SDS Number:
1731675-00017

Date of last issue: 14.04.2025
Date of first issue: 05.06.2017

tem; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN